Document 2798
 DOCN  M94A2798
 TI    Evaluation of long term oral administration of glycyrrhizin in
       asymptomatic HIV-1 carrier.
 DT    9412
 AU    Kinoshita S; Tsujino G; Yoshioka K; Akatani K; Imai M; Ikegami N; Osaka
       National Hospital, Japan.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):222 (abstract no. PB0317). Unique
       Identifier : AIDSLINE ICA10/94369777
 AB    OBJECTIVE: The study was aimed at evaluating clinically and
       immunologically the effectiveness of long-term oral administration of
       glycyrrhizin (GL) to asymptomatic HIV-1 carrier (AC) to delay or prevent
       the disease progression. METHODS: Daily dose of 150-225 mg of GL was
       given to AC hemophiliac patients since 1987 in the first group, and
       since 1989-1990 in the second group. CD4+ and CD8+ T cell counts in
       blood samples and p24 antigens (Ag) in sera were monitored. RESULTS:
       When GL was given to AC patients at a stage of their CD4+ cell counts >
       500/ul, their CD4+ counts have been maintained > 500/ul up to now. When
       GL was given to patients at a stage of the CD4+ counts between 200-500
       per ul, their CD4 counts have been maintained > 200/ul. P24 Ag was not
       detected in their sera throughout the period. CONCLUSION: Long-term oral
       administration of GL from an early stage of asymptomatic HIV-1 carriers
       is effective to maintain their AC stages without any side effects and
       disease development for a long time.
 DE    Acquired Immunodeficiency Syndrome/PREVENTION & CONTROL  Adjuvants,
       Immunologic/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE  Administration,
       Oral  Carrier State/*DRUG THERAPY  Cohort Studies  Glycyrrhetinic
       Acid/*ANALOGS & DERIVATIVES/ADMINISTRATION &  DOSAGE/THERAPEUTIC USE
       Hemophilia/COMPLICATIONS  Human  HIV Core Protein p24/BLOOD  HIV
       Infections/COMPLICATIONS/*DRUG THERAPY  *HIV-1  Leukocyte Count  T4
       Lymphocytes  CLINICAL TRIAL  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).